We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Veins of gold

27 February 2004 By Robert Cyran

Investors have got that message sort of. But they still seem to be seriously underestimating Avastin’s potential. Estimates of $1bn$2bn a year in peak sales look low. It could easily be double that.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)